1. The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations
   Chih-Jen Yang et al, 2017, BMC Pharmacology and Toxicology CrossRef
2. Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
   Lara Kujtan et al, 2019, Expert Review of Anticancer Therapy CrossRef